249 related articles for article (PubMed ID: 33884410)
1. An update on the role of anti-IL-12/IL23 agents in the management of inflammatory bowel disease.
Nigam GB; Limdi JK
Br Med Bull; 2021 Jun; 138(1):29-40. PubMed ID: 33884410
[TBL] [Abstract][Full Text] [Related]
2. A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.
Verstockt B; Deleenheer B; Van Assche G; Vermeire S; Ferrante M
Expert Opin Drug Saf; 2017 Jul; 16(7):809-821. PubMed ID: 28573876
[TBL] [Abstract][Full Text] [Related]
3. Anti-interleukin-23 agents for the treatment of ulcerative colitis.
Hanžel J; D'Haens GR
Expert Opin Biol Ther; 2020 Apr; 20(4):399-406. PubMed ID: 31760827
[No Abstract] [Full Text] [Related]
4. Research progress of Ustekinumab in the treatment of inflammatory bowel disease.
Zhang W; Zhong G; Ren X; Li M
Front Immunol; 2024; 15():1322054. PubMed ID: 38455044
[TBL] [Abstract][Full Text] [Related]
5. Blockade of IL-23: What is in the Pipeline?
Parigi TL; Iacucci M; Ghosh S
J Crohns Colitis; 2022 May; 16(Supplement_2):ii64-ii72. PubMed ID: 35553666
[TBL] [Abstract][Full Text] [Related]
6. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
Fiorino G; Allocca M; Correale C; Roda G; Furfaro F; Loy L; Zilli A; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2020 Apr; 20(4):421-427. PubMed ID: 32027523
[No Abstract] [Full Text] [Related]
7. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.
Verstockt B; Van Assche G; Vermeire S; Ferrante M
Expert Opin Biol Ther; 2017 Jan; 17(1):31-47. PubMed ID: 27817215
[TBL] [Abstract][Full Text] [Related]
8. Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases.
Abraham C; Dulai PS; Vermeire S; Sandborn WJ
Gastroenterology; 2017 Feb; 152(2):374-388.e4. PubMed ID: 27780712
[TBL] [Abstract][Full Text] [Related]
9. New treatment options for inflammatory bowel diseases.
Verstockt B; Ferrante M; Vermeire S; Van Assche G
J Gastroenterol; 2018 May; 53(5):585-590. PubMed ID: 29556726
[TBL] [Abstract][Full Text] [Related]
10. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?
Argollo MC; Allocca M; Furfaro F; Peyrin-Biroulet L; Danese S
Curr Pharm Des; 2019; 25(1):25-31. PubMed ID: 31092171
[TBL] [Abstract][Full Text] [Related]
12. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.
Wong U; Cross RK
Expert Opin Investig Drugs; 2019 May; 28(5):473-479. PubMed ID: 30884245
[TBL] [Abstract][Full Text] [Related]
13. [Biologic therapies in chronic inflammatory bowel diseases].
Reenaers C; Louis E; Belaiche J
Rev Med Liege; 2009; 64(5-6):301-4. PubMed ID: 19642463
[TBL] [Abstract][Full Text] [Related]
14. Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease.
Almradi A; Hanzel J; Sedano R; Parker CE; Feagan BG; Ma C; Jairath V
BioDrugs; 2020 Dec; 34(6):713-721. PubMed ID: 33105016
[TBL] [Abstract][Full Text] [Related]
15. Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab.
Pugliese D; Privitera G; Fiorani M; Parisio L; Calvez V; Papa A; Gasbarrini A; Armuzzi A
Therap Adv Gastroenterol; 2022; 15():17562848221102283. PubMed ID: 35721840
[TBL] [Abstract][Full Text] [Related]
16. IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?
Ma C; Panaccione R; Khanna R; Feagan BG; Jairath V
Best Pract Res Clin Gastroenterol; 2019; 38-39():101604. PubMed ID: 31327402
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
18. IL-23 Monoclonal Antibodies for IBD: So Many, So Different?
McDonald BD; Dyer EC; Rubin DT
J Crohns Colitis; 2022 May; 16(Supplement_2):ii42-ii53. PubMed ID: 35553664
[TBL] [Abstract][Full Text] [Related]
19. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A; Colombel JF; Ungaro R
Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
[TBL] [Abstract][Full Text] [Related]
20. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
Toussirot E
Inflamm Allergy Drug Targets; 2012 Apr; 11(2):159-68. PubMed ID: 22280236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
